DK1691824T3 - Proteiner tilhörende BCL-2-familien og fragmenter deraf og deres anvendelse i cancerpatienter - Google Patents

Proteiner tilhörende BCL-2-familien og fragmenter deraf og deres anvendelse i cancerpatienter

Info

Publication number
DK1691824T3
DK1691824T3 DK04797460T DK04797460T DK1691824T3 DK 1691824 T3 DK1691824 T3 DK 1691824T3 DK 04797460 T DK04797460 T DK 04797460T DK 04797460 T DK04797460 T DK 04797460T DK 1691824 T3 DK1691824 T3 DK 1691824T3
Authority
DK
Denmark
Prior art keywords
fragments
bcl
family
cancer patients
proteins belonging
Prior art date
Application number
DK04797460T
Other languages
Danish (da)
English (en)
Inventor
Eivind Per Thor Straten
Mads Hald Andersen
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK1691824T3 publication Critical patent/DK1691824T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04797460T 2003-11-19 2004-11-18 Proteiner tilhörende BCL-2-familien og fragmenter deraf og deres anvendelse i cancerpatienter DK1691824T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52311903P 2003-11-19 2003-11-19
DKPA200301716 2003-11-19
PCT/DK2004/000799 WO2005049073A2 (en) 2003-11-19 2004-11-18 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients

Publications (1)

Publication Number Publication Date
DK1691824T3 true DK1691824T3 (da) 2009-07-06

Family

ID=39149116

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09154734.9T DK2087904T3 (da) 2003-11-19 2004-11-18 Terapeutisk anvendelse af peptider stammende fra Bcl-XL-protein i cancerpatienter
DK04797460T DK1691824T3 (da) 2003-11-19 2004-11-18 Proteiner tilhörende BCL-2-familien og fragmenter deraf og deres anvendelse i cancerpatienter

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09154734.9T DK2087904T3 (da) 2003-11-19 2004-11-18 Terapeutisk anvendelse af peptider stammende fra Bcl-XL-protein i cancerpatienter

Country Status (17)

Country Link
US (1) US7842294B2 (enExample)
EP (2) EP1691824B1 (enExample)
JP (2) JP4926714B2 (enExample)
KR (2) KR101284237B1 (enExample)
CN (1) CN1921878B (enExample)
AT (1) ATE424842T1 (enExample)
AU (1) AU2004290866B2 (enExample)
CA (1) CA2546794C (enExample)
DE (1) DE602004019965D1 (enExample)
DK (2) DK2087904T3 (enExample)
ES (2) ES2436429T3 (enExample)
MX (1) MXPA06005738A (enExample)
PL (2) PL2087904T3 (enExample)
PT (1) PT1691824E (enExample)
RU (1) RU2367468C2 (enExample)
WO (1) WO2005049073A2 (enExample)
ZA (1) ZA200604866B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
ES2661082T3 (es) * 2003-01-30 2018-03-27 Survac Aps Péptidos derivados de survivina y uso de los mismos
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
CN101438437A (zh) * 2004-10-19 2009-05-20 麻省理工学院 用于自组装、柔软和轻的锂电池组的病毒支架
AU2011203535B2 (en) * 2005-02-04 2012-10-11 Survac Aps Survivin peptide vaccine
EP1853305B1 (en) * 2005-02-04 2014-08-20 Survac ApS Survivin peptide vaccine
AU2006347606B2 (en) * 2005-09-09 2012-10-11 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting cell death or enhancing cell proliferation
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3620465B1 (en) * 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
EP2254592B1 (en) * 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
AU2009246876B2 (en) 2008-05-16 2015-04-02 Htyr Acquisition Llc Antibodies and processes for preparing the same
CA2730369A1 (en) * 2008-07-16 2010-01-21 Burnham Institute For Medical Research Compositions and methods for modulating nod-like receptor activity and uses thereof
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
CA2735522C (en) 2008-08-28 2017-04-18 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
AU2009305617B2 (en) 2008-10-17 2014-01-23 University Of Miami Tumor vaccine
EP3444333A1 (en) * 2009-10-22 2019-02-20 Thomas Jefferson University Cell-based anti-cancer compositions and methods of making and using the same
CN102884190B (zh) 2010-03-11 2016-03-23 肿瘤疗法科学股份有限公司 Hjurp肽及包含它们的疫苗
EP2608799B1 (en) * 2010-08-24 2018-12-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
SI3536334T1 (sl) 2012-05-16 2021-11-30 Stemline Therapeutics Inc. Cepiva proti raku, ki ciljajo na rakave matične celice
SG10201700459XA (en) * 2012-07-20 2017-02-27 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US20160017011A1 (en) * 2013-02-26 2016-01-21 Rongfu Wang Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
CA2902423C (en) * 2013-03-01 2021-06-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
US9704181B2 (en) * 2014-05-06 2017-07-11 International Business Machines Corporation Real-time social group based bidding system
CN113786476A (zh) 2016-12-02 2021-12-14 泰加生物工艺学公司 纳米颗粒调配物
TWI796314B (zh) * 2017-01-27 2023-03-21 德商英麥提克生物技術股份有限公司 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
CR20210128A (es) 2017-01-27 2021-04-26 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cancer (divisional exp. 2019-388)
US11666644B2 (en) 2018-09-04 2023-06-06 Treos Bio Limited Peptide vaccines
EP3898666A2 (en) 2018-12-17 2021-10-27 Immudex ApS Panel comprising borrelia mhc multimers
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
EP3969041A4 (en) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
CN113355432A (zh) * 2021-05-12 2021-09-07 甘肃农业大学 Bmf作为细胞凋亡标志物的应用
WO2022245249A1 (ru) * 2021-05-17 2022-11-24 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Пептидные соединения для индукции апоптоза в опухолевой клетке

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
ATE280180T1 (de) 1992-08-31 2004-11-15 Ludwig Inst Cancer Res Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
US5470955A (en) 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5789201A (en) * 1996-02-23 1998-08-04 Cocensys, Inc. Genes coding for bcl-y a bcl-2 homologue
US6245523B1 (en) 1996-11-20 2001-06-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
WO1998058541A1 (en) * 1997-06-24 1998-12-30 Dana-Farber Cancer Institute, Inc. Modulation of apoptosis
WO2001036594A1 (en) * 1999-11-16 2001-05-25 Dartmouth College Mcl-1 GENE REGULATORY ELEMENTS AND A PRO-APOPTOTIC Mcl-1 VARIANT
AU2578401A (en) * 1999-12-14 2001-06-25 Burnham Institute, The Bcl-g polypeptides, encoding nucleic acids and methods of use
WO2002005835A2 (en) * 2000-07-17 2002-01-24 Washington University Modulation of apoptosis
AU2002257647A1 (en) 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
AU2004228106B2 (en) 2003-04-11 2010-05-13 Survac Aps Therapeutic cancer vaccine

Also Published As

Publication number Publication date
KR101216655B1 (ko) 2013-01-02
US20080050396A1 (en) 2008-02-28
CN1921878A (zh) 2007-02-28
ES2323588T3 (es) 2009-07-21
DE602004019965D1 (de) 2009-04-23
AU2004290866B2 (en) 2010-09-02
EP1691824B1 (en) 2009-03-11
CN1921878B (zh) 2012-04-25
EP2087904B1 (en) 2013-08-28
ZA200604866B (en) 2008-05-28
EP2087904A1 (en) 2009-08-12
JP5502823B2 (ja) 2014-05-28
WO2005049073A3 (en) 2006-01-05
MXPA06005738A (es) 2006-12-14
JP4926714B2 (ja) 2012-05-09
ES2436429T3 (es) 2014-01-02
CA2546794C (en) 2013-09-17
WO2005049073A2 (en) 2005-06-02
JP2007511547A (ja) 2007-05-10
CA2546794A1 (en) 2005-06-02
AU2004290866A1 (en) 2005-06-02
KR20060132622A (ko) 2006-12-21
JP2011246496A (ja) 2011-12-08
US7842294B2 (en) 2010-11-30
DK2087904T3 (da) 2013-12-02
PT1691824E (pt) 2009-05-28
KR20130026527A (ko) 2013-03-13
EP1691824A2 (en) 2006-08-23
RU2006121466A (ru) 2007-12-27
PL1691824T3 (pl) 2009-08-31
KR101284237B1 (ko) 2013-07-09
ATE424842T1 (de) 2009-03-15
HK1101131A1 (en) 2007-10-12
RU2367468C2 (ru) 2009-09-20
PL2087904T3 (pl) 2014-01-31

Similar Documents

Publication Publication Date Title
DK1691824T3 (da) Proteiner tilhörende BCL-2-familien og fragmenter deraf og deres anvendelse i cancerpatienter
CY1119127T1 (el) Επιτοποι σκληροστινης
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
NZ576467A (en) Smoothened polypeptides and methods of use
DE602004029393D1 (de) Tgf-beta1-bindende und geträgerte peptide
CA2523467C (en) Treatment of t-cell mediated diseases
SE0103754L (sv) Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
AU2003270643A1 (en) Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
EP1553966A4 (en) POLYPEPTIDES OF HUMAN PAPILLOMA AND IMMUNOGENIC COMPOSITIONS
ATE460176T1 (de) Mikrosomvakzin
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
ATE412671T1 (de) Modifizierter faktor viii
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
DK1290160T3 (da) Humane Pellino-polypeptider
CY1114002T1 (el) Κοντα βιοδραστικα πεπτιδια για κυτταρικη και ανοσολογικη τροποποιηση
ATE475670T1 (de) Konsensus-peptid
FR2870126B1 (fr) Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
EA200801411A1 (ru) Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
ATE473756T1 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs
ATE400581T1 (de) Peptid-antioxidantien aus sojaproteinen
ATE484290T1 (de) Peptid mit antitumoraler wirkung
CY1108761T1 (el) Απενεργοποιημενες κυτοκινες για ανοσοποιηση